Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Clostridium difficile: development of a novel candidate vaccine.

Foglia G, Shah S, Luxemburger C, Pietrobon PJ.

Vaccine. 2012 Jun 19;30(29):4307-9. doi: 10.1016/j.vaccine.2012.01.056. Review.

PMID:
22682287
2.

Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.

Anosova NG, Brown AM, Li L, Liu N, Cole LE, Zhang J, Mehta H, Kleanthous H.

J Med Microbiol. 2013 Sep;62(Pt 9):1394-404. doi: 10.1099/jmm.0.056796-0. Epub 2013 Mar 21.

PMID:
23518659
3.

Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.

Karczewski J, Zorman J, Wang S, Miezeiewski M, Xie J, Soring K, Petrescu I, Rogers I, Thiriot DS, Cook JC, Chamberlin M, Xoconostle RF, Nahas DD, Joyce JG, Bodmer JL, Heinrichs JH, Secore S.

Vaccine. 2014 May 19;32(24):2812-8. doi: 10.1016/j.vaccine.2014.02.026. Epub 2014 Mar 21.

PMID:
24662701
4.

A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.

Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J, Savidge T, Feng H.

Infect Immun. 2012 Aug;80(8):2678-88. doi: 10.1128/IAI.00215-12. Epub 2012 May 21.

5.

The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model.

Yang XQ, Zhao YG, Chen XQ, Jiang B, Sun DY.

BMC Gastroenterol. 2013 Jul 17;13:117. doi: 10.1186/1471-230X-13-117.

6.

Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Kyne L, Warny M, Qamar A, Kelly CP.

N Engl J Med. 2000 Feb 10;342(6):390-7.

7.

IgG antibody response to toxins A and B in patients with Clostridium difficile infection.

Wullt M, Norén T, Ljungh A, Åkerlund T.

Clin Vaccine Immunol. 2012 Sep;19(9):1552-4. doi: 10.1128/CVI.00210-12. Epub 2012 Jul 11.

8.

Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.

Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, Giannasca PJ, Monath TP, Kelly CP.

Infect Immun. 2003 Mar;71(3):1608-10.

9.

Mouse relapse model of Clostridium difficile infection.

Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H.

Infect Immun. 2011 Jul;79(7):2856-64. doi: 10.1128/IAI.01336-10. Epub 2011 May 16.

10.

Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.

Permpoonpattana P, Hong HA, Phetcharaburanin J, Huang JM, Cook J, Fairweather NF, Cutting SM.

Infect Immun. 2011 Jun;79(6):2295-302. doi: 10.1128/IAI.00130-11. Epub 2011 Apr 11.

11.

Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.

Monaghan TM, Robins A, Knox A, Sewell HF, Mahida YR.

PLoS One. 2013 Sep 10;8(9):e74452. doi: 10.1371/journal.pone.0074452. eCollection 2013.

12.

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

Leav BA, Blair B, Leney M, Knauber M, Reilly C, Lowy I, Gerding DN, Kelly CP, Katchar K, Baxter R, Ambrosino D, Molrine D.

Vaccine. 2010 Jan 22;28(4):965-9. doi: 10.1016/j.vaccine.2009.10.144. Epub 2009 Nov 24.

PMID:
19941990
14.

Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile.

Johnson S, Gerding DN, Janoff EN.

J Infect Dis. 1992 Dec;166(6):1287-94.

PMID:
1431247
15.

Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease.

Steele J, Mukherjee J, Parry N, Tzipori S.

J Infect Dis. 2013 Jan 15;207(2):323-30. doi: 10.1093/infdis/jis669. Epub 2012 Nov 2.

16.

A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.

Yang Z, Schmidt D, Liu W, Li S, Shi L, Sheng J, Chen K, Yu H, Tremblay JM, Chen X, Piepenbrink KH, Sundberg EJ, Kelly CP, Bai G, Shoemaker CB, Feng H.

J Infect Dis. 2014 Sep 15;210(6):964-72. doi: 10.1093/infdis/jiu196. Epub 2014 Mar 27.

17.

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Yang Z, Ramsey J, Hamza T, Zhang Y, Li S, Yfantis HG, Lee D, Hernandez LD, Seghezzi W, Furneisen JM, Davis NM, Therien AG, Feng H.

Infect Immun. 2015 Feb;83(2):822-31. doi: 10.1128/IAI.02897-14. Epub 2014 Dec 8.

18.
19.

Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, Xu H, Leffler DA, Kelly CP.

Gastroenterology. 2009 Apr;136(4):1206-14. doi: 10.1053/j.gastro.2008.12.038. Epub 2008 Dec 13.

PMID:
19162027
20.

Clostridium difficile and the disease it causes.

Norén T.

Methods Mol Biol. 2010;646:9-35. doi: 10.1007/978-1-60327-365-7_2.

PMID:
20597000
Items per page

Supplemental Content

Write to the Help Desk